Rational development of radiopharmaceuticals for HIV-1

Nuclear Medicine and Biology

Volumn 41, Issue 4, 2014, Pages 299-308

  Lau, Chuen Yen ^a   Maldarelli, Frank ^a   Eckelman, William C ^b   Neumann, Ronald D ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Molecular Tracer LLC   (United States)

Author keywords

Human Immunodeficiency Virus; Infectious disease imaging; Radiopharmaceutical

Indexed keywords

BIOLOGICAL FACTOR; FLUORODEOXYGLUCOSE; RADIOPHARMACEUTICAL AGENT;

CELLULAR DISTRIBUTION; DISEASE ASSOCIATION; DISEASE MODEL; DRUG DESIGN; DRUG DISTRIBUTION; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; INFLAMMATION; LIFE CYCLE; MANAGED CARE; MOLECULAR IMAGING; NONHUMAN; PERSISTENT VIRUS INFECTION; RADIOCHEMISTRY; REVIEW; VIRION; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS MORPHOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE IMAGING; RADIOPHARMACEUTICAL;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG DISCOVERY; HIV INFECTIONS; HUMANS; RADIOPHARMACEUTICALS;

EID: 84895474751     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.01.005     Document Type: Review

References (87)

1. Joint United Nations Programme on HIV/AIDS Global report: UNAIDS report on the global AIDS epidemic 2012 2012, UNAIDS, Geneva.
2. Stanford University HIV drug resistance database 2013.
3. Churchill M., Nath A. Where does HIV hide? A focus on the central nervous system. Curr Opin HIV AIDS 2013, 8:165-169.
4. Nixon C.C., Vatakis D.N., Reichelderfer S.N., Dixit D., Kim S.G., Uittenbogaart C.H., et al. HIV-1 Infection of hematopoietic progenitor cells in vivo in humanized mice. Blood 2013.
5. Xing S., Siliciano R.F. Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today 2013, 18:541-551.
6. Chun T.W. Tracking replication-competent HIV reservoirs in infected individuals. Curr Opin HIV AIDS 2013, 8:111-116.
7. Di Mascio M., Paik C.H., Carrasquillo J.A., Maeng J.S., Jang B.S., Shin I.S., et al. Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates. Blood 2009, 114:328-337.
8. Iyengar S., Chin B., Margolick J.B., Sabundayo B.P., Schwartz D.H. Anatomical loci of HIV-associated immune activation and association with viraemia. Lancet 2003, 362:945-950.
9. Brust D., Polis M., Davey R., Hahn B., Bacharach S., Whatley M., et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS 2006, 20:495-503.
10. Best B.M., Letendre S.L., Brigid E., Clifford D.B., Collier A.C., Gelman B.B., et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS 2009, 23:83-87.
11. Best B.M., Letendre S.L., Koopmans P., Rossi S.S., Clifford D.B., Collier A.C., et al. Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr 2012, 59:376-381.
12. Letendre S., Marquie-Beck J., Capparelli E., Best B., Clifford D., Collier A.C., et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008, 65:65-70.
13. Cory T.J., Schacker T.W., Stevenson M., Fletcher C.V. Overcoming pharmacologic sanctuaries. Curr Opin HIV AIDS 2013, 8:190-195.
14. Bryan R.A., Guimaraes A.J., Hopcraft S., Jiang Z., Bonilla K., Morgenstern A., et al. Toward developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigens. Mycopathologia 2012, 173:463-471.
15. Harris M., Wang X.G., Jiang Z., Goldberg G.L., Casadevall A., Dadachova E. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line. Head Neck Oncol 2011, 3:9.
16. Harris M., Wang X.G., Jiang Z., Phaeton R., Koba W., Goldberg G.L., et al. Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein. Br J Cancer 2013, 108:859-865.
17. Jandl T., Revskaya E., Jiang Z., Bryan R.A., Casadevall A., Dadachova E. Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma. Immunotherapy 2013, 5:357-364.
18. Jandl T., Revskaya E., Jiang Z., Harris M., Dorokhova O., Tsukrov D., et al. Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy. Nucl Med Biol 2013, 40:177-181.
19. Klein M., Lotem M., Peretz T., Zwas S.T., Mizrachi S., Liberman Y., et al. Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma. J Skin Cancer 2013, 2013:828329.
20. Brenchley J.M., Schacker T.W., Ruff L.E., Price D.A., Taylor J.H., Beilman G.J., et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004, 200:749-759.
21. Jamar F., Buscombe J., Chiti A., Christian P.E., Delbeke D., Donohoe K.J., et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med 2013, 54:647-658.
22. Brewer S., McPherson M., Fujiwara D., Turovskaya O., Ziring D., Chen L., et al. Molecular imaging of murine intestinal inflammation with 2-deoxy-2-[18F]fluoro-d-glucose and positron emission tomography. Gastroenterology 2008, 135:744-755.
23. Higashikawa K., Akada N., Yagi K., Watanabe K., Kamino S., Kanayama Y., et al. Exploration of target molecules for molecular imaging of inflammatory bowel disease. Biochem Biophys Res Commun 2011, 410:416-421.
24. Wang H., Machtaler S., Bettinger T., Lutz A.M., Luong R., Bussat P., et al. Molecular imaging of inflammation in inflammatory bowel disease with a clinically translatable dual-selectin-targeted US contrast agent: comparison with FDG PET/CT in a mouse model. Radiology 2013, 267:818-829.
25. Hindryckx P., Staelens S., Devisscher L., Deleye S., De Vos F., Delrue L., et al. Longitudinal quantification of inflammation in the murine dextran sodium sulfate-induced colitis model using muPET/CT. Inflamm Bowel Dis 2011, 17:2058-2064.
26. Ren W., Muzik O., Jackson N., Khoury B., Shi T., Flynn J.C., et al. Differentiation of septic and aseptic loosening by PET with both 11C-PK11195 and 18F-FDG in rat models. Nucl Med Commun 2012, 33:747-756.
27. Irmler I.M., Opfermann T., Gebhardt P., Gajda M., Brauer R., Saluz H.P., et al. In vivo molecular imaging of experimental joint inflammation by combined (18)F-FDG positron emission tomography and computed tomography. Arthritis Res Ther 2010, 12:R203.
28. Schopf L., Anderson K., Jaffe B. Rat models of arthritis: similarities, differences, advantages and disadvantages in the identification of novel therapeutics. In vivo models of inflammation: progress in inflammation research 2006, 1-34. Birkhauser Verlag Basel, Switzerland. C. Stevenson, L. Marshall, D. Morgan (Eds.).
29. Jones-Jackson L., Walker R., Purnell G., McLaren S.G., Skinner R.A., Thomas J.R., et al. Early detection of bone infection and differentiation from post-surgical inflammation using 2-deoxy-2-[18F]-fluoro-d-glucose positron emission tomography (FDG-PET) in an animal model. J Orthop Res 2005, 23:1484-1489.
30. Lin P.W., Liu R.S., Liou T.H., Pan L.C., Chen C.H. Correlation between joint [F-18] FDG PET uptake and synovial TNF-alpha concentration: a study with two rabbit models of acute inflammatory arthritis. Appl Radiat Isot 2007, 65:1221-1226.
31. Liu P., Huang G., Dong S., Wan L. Kinetic analysis of experimental rabbit tumour and inflammation model with 18F-FDG PET/CT. Nuklearmedizin. Nucl Med 2009, 48:153-158.
32. Davies J.R., Izquierdo-Garcia D., Rudd J.H., Figg N., Richards H.K., Bird J.L., et al. FDG-PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis. Int J Cardiovasc Imaging 2010, 26:41-48.
33. Schroeter M., Dennin M.A., Walberer M., Backes H., Neumaier B., Fink G.R., et al. Neuroinflammation extends brain tissue at risk to vital peri-infarct tissue: a double tracer [11C]PK11195- and [18F]FDG-PET study. J Cereb Blood Flow Metab 2009, 29:1216-1225.
34. Radu C.G., Shu C.J., Shelly S.M., Phelps M.E., Witte O.N. Positron emission tomography with computed tomography imaging of neuroinflammation in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2007, 104:1937-1942.
35. Jonsson C.B., Camp J.V., Wu A., Zheng H., Kraenzle J.L., Biller A.E., et al. Molecular imaging reveals a progressive pulmonary inflammation in lower airways in ferrets infected with 2009 H1N1 pandemic influenza virus. PloS one 2012, 7:e40094.
36. Kawai S., Ikeda E., Sugiyama M., Matsumoto J., Higuchi T., Zhang H., et al. Enhancement of splenic glucose metabolism during acute malarial infection: correlation of findings of FDG-PET imaging with pathological changes in a primate model of severe human malaria. Am J Trop Med Hyg 2006, 74:353-360.
37. Sugiyama M., Ikeda E., Kawai S., Higuchi T., Zhang H., Khan N., et al. Cerebral metabolic reduction in severe malaria: fluorodeoxyglucose-positron emission tomography imaging in a primate model of severe human malaria with cerebral involvement. Am J Trop Med Hyg 2004, 71:542-545.
38. Zhao S., Kuge Y., Kohanawa M., Takahashi T., Kawashima H., Temma T., et al. Extensive FDG uptake and its modification with corticosteroid in a granuloma rat model: an experimental study for differentiating granuloma from tumors. Eur J Nucl Med Mol Imaging 2007, 34:2096-2105.
39. Yamada S., Kubota K., Kubota R., Ido T., Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995, 36:1301-1306.
40. Hamazawa Y., Koyama K., Okamura T., Wada Y., Wakasa T., Okuma T., et al. Comparison of dynamic FDG-microPET study in a rabbit turpentine-induced inflammatory model and in a rabbit VX2 tumor model. Ann Nucl Med 2007, 21:47-55.
41. Rao V.K., Carrasquillo J.A., Dale J.K., Bacharach S.L., Whatley M., Dugan F., et al. Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS). Am J Hematol 2006, 81:81-85.
42. Malech H. Evaluation of patients with immune function abnormalities 2013.
43. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
44. Chang C.H., Curtis J.D., Maggi L.B., Faubert B., Villarino A.V., O'Sullivan D., et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 2013, 153:1239-1251.
45. Fischer B.M., Olsen M.W., Ley C.D., Klausen T.L., Mortensen J., Hojgaard L., et al. How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study. Eur J Nucl Med Mol Imaging 2006, 33:697-702.
46. Vu N.T., Yu Z.T., Comin-Anduix B., Sondergaard J.N., Silverman R.W., Chang C.Y., et al. A beta-camera integrated with a microfluidic chip for radioassays based on real-time imaging of glycolysis in small cell populations. J Nucl Med 2011, 52:815-821.
47. Hatziioannou T., Evans D.T. Animal models for HIV/AIDS research. Nature reviews. Microbiology 2012, 10:852-867.
48. Thippeshappa R., Ruan H., Kimata J.T. Breaking barriers to an AIDS model with macaque-tropic HIV-1 derivatives. Biology 2012, 1:134-164.
49. Webb D.R. Animal models of human disease: inflammation. Biochem Pharmacol 2013.
50. Marchetti G., Tincati C., Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev 2013, 26:2-18.
51. Tabb B., Morcock D.R., Trubey C.M., Quinones O.A., Hao X.P., Smedley J., et al. Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving anti-tumor necrosis factor treatment during primary simian immunodeficiency virus infection. J Infect Dis 2013, 207:880-892.
52. Zink M.C., Brice A.K., Kelly K.M., Queen S.E., Gama L., Li M., et al. Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis 2010, 202:161-170.
53. Clements J.E., Gama L., Graham D.R., Mankowski J.L., Zink M.C. A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system. Curr Opin HIV AIDS 2011, 6:37-42.
54. Apetrei C., Pandrea A., Mellors J. Nonhuman primate models for HIV cure research. PLoS Pathog 2012, 8.
55. Los Alamos National Laboratory HIV sequence compendium 2012. Theoretical biology and biophysics 2012, Los Alamos National Laboratory, Los Alamos, New Mexico. B.F. Carla Kuiken, T. Leitner, C. Apetrei, B. Hahn, I. Mizrachi, J. Mullins, A. Rambaut, S. Wolinsky, B. Korber (Eds.).
56. Los Alamos National Laboratory HIV sequence database 2013.
57. National Institute of Allergy and Infectious Disease How HIV causes AIDS 2004, National Institutes Health, Bethesda, MD.
58. Josefsson L., Palmer S., Faria N.R., Lemey P., Casazza J., Ambrozak D., et al. Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T-cells contain one HIV-1 DNA molecule. PLoS Pathog 2013, 9:e1003432.
59. National Institute of Allergy and Infectious Disease HIV replication cycle 2012, National Institutes Health, Bethesda, MD.
60. Ho Y.-C., Shan L., Hosmane N.N., Wang J., Laskey S.B., Rosenbloom D.I., et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013, 155:540-551.
61. Chun T.W., Carruth L., Finzi D., Shen X., DiGiuseppe J.A., Taylor H., et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188.
62. Dadachova E., Kitchen S.G., Bristol G., Baldwin G.C., Revskaya E., Empig C., et al. Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication. PloS one 2012, 7:e31866.
63. Dadachova E., Tsukrov D., McFarren A. Radiolabeled antibody to gp41 HIV glycoprotein kills ART-treated lymphocytes from HIV patients and HIV infected monocytes in human blood brain barrier model. Presentation at Radiological Society of North America. Chicago Dec 3 2013.
64. Imbeault M., Giguere K., Ouellet M., Tremblay M.J. Exon level transcriptomic profiling of HIV-1-infected CD4(+) T cells reveals virus-induced genes and host environment favorable for viral replication. PLoS Pathog 2012, 8:e1002861.
65. Liang W.S., Maddukuri A., Teslovich T.M., de la Fuente C., Agbottah E., Dadgar S., et al. Therapeutic targets for HIV-1 infection in the host proteome. Retrovirology 2005, 2:20.
66. Capalbo G., Muller-Kuller T., Ottmann O.G., Hoelzer D., Scheuring U.J. HIV-1 infection suppresses expression of host cell cycle-associated gene PDS5A. Intervirology 2012, 55:263-275.
67. Kim S.Y., Li J., Bentsman G., Brooks A.I., Volsky D.J. Microarray analysis of changes in cellular gene expression induced by productive infection of primary human astrocytes: implications for HAD. J Neuroimmunol 2004, 157:17-26.
68. Bray M., Di Mascio M., de Kok-Mercado F., Mollura D.J., Jagoda E. Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes. Antiviral Res 2010, 88:129-142.
69. Kuruppu D., Brownell A.L., Zhu A., Yu M., Wang X., Kulu Y., et al. Positron emission tomography of herpes simplex virus 1 oncolysis. Cancer Res 2007, 67:3295-3300.
70. Mishani E., Hagooly A. Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer. J Nucl Med 2009, 50:1199-1202.
71. Eckelman W.C., Jones A.G., Duatti A., Reba R.C. Progress using Tc-99m radiopharmaceuticals for measuring high capacity sites and low density sites. Drug Discov Today 2013, 18:984-991.
72. Archin N.M., Liberty A.L., Kashuba A.D., Choudhary S.K., Kuruc J.D., Crooks A.M., et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012, 487:482-485.
73. Lewin S. HIV latency and eradication: clinical perspectives. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington 2012.
74. Rasmussen T.A., Schmeltz Sogaard O., Brinkmann C., Wightman F., Lewin S.R., Melchjorsen J., et al. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 2013, 9.
75. Rasmussen T.A., Tolstrup M., Winckelmann A., Ostergaard L., Sogaard O.S. Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother 2013, 9.
76. Shirakawa K., Chavez L., Hakre S., Calvanese V., Verdin E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 2013, 21:277-285.
77. Aginagalde M., Gomez-Vallejo V., Vara Y., Cossio F.P., Llop J. Synthesis of 11C-labeled Kendine 91, a histone deacetylase inhibitor. Appl Radiat Isot 2012, 70:2552-2557.
78. Hendricks J.A., Keliher E.J., Marinelli B., Reiner T., Weissleder R., Mazitschek R. In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA). J Med Chem 2011, 54:5576-5582.
79. Zeglis B.M., Pillarsetty N., Divilov V., Blasberg R.A., Lewis J.S. The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer. Nucl Med Biol 2011, 38:683-696.
80. Deeks S.G. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011, 62:141-155.
81. Hunt P.W. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012, 9:139-147.
82. Kuller L.H., Tracy R., Belloso W., De Wit S., Drummond F., Lane H.C., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008, 5:e203.
83. Sigal A., Kim J.T., Balazs A.B., Dekel E., Mayo A., Milo R., et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011, 477:95-98.
84. Roberts A.I., Devadas S., Zhang X., Zhang L., Keegan A., Greeneltch K., et al. The role of activation-induced cell death in the differentiation of T-helper-cell subsets. Immunol Res 2003, 28:285-293.
85. Zheng L., Trageser C.L., Willerford D.M., Lenardo M.J. T cell growth cytokines cause the superinduction of molecules mediating antigen-induced T lymphocyte death. J Immunol 1998, 160:763-769.
86. Naeger D.M., Martin J.N., Sinclair E., Hunt P.W., Bangsberg D.R., Hecht F., et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PloS one 2010, 5:e8886.
87. Ipp H., Zemlin A. The paradox of the immune response in HIV infection: when inflammation becomes harmful. Clin Chim Acta 2013, 416:96-99.